Results 121 to 130 of about 16,301 (208)

ENHANCING SOLUBILITY AND DISSOLUTION OF FENOFIBRATE BY SPRAY DRYING TECHNIQUE [PDF]

, 2015
Objective: Fenofibrate, a hypolipidemic drug agent, exhibits poor water solubility and dissolution. Thus, the aim of the present study was to improve the solubility and dissolution rate of Fenofibrate by preparing microspheres by spray drying technique ...
Dixit, Mudit, Rasheed, Abdul, Daniel, Sudi, Fijaz Rahman, Narayana Charyulu   +3 more
core  

Formulation Development and Evaluation of Fenofibrate Capsule [PDF]

, 2012
The present study An antilipemic agent, fenofibrate decreases the levels of fatty substances in the blood. Fenofibrate compound belongs to BCS-II classification (drug with very low solubility and has high lipophilicity). Dissolution rate of fenofibrate
Ramvikas, M
core  

Combination of fenofibrate with non-statin drug regimens

, 2010
OBJECTIVE: We present the available data on the effects of combined therapy of fenofibrate with drugs affecting lipid metabolism other than statins. METHODS: We consider studies evaluating the effects of combined therapy of fenofibrate with bile acid ...
Elisaf, M. S., Agouridis, A. P., Mikhailidis, D. P., Filippatos, T. D., Derdemezis, C. S.   +4 more
core  

Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins. [PDF]

Front Cardiovasc Med
Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Farnier M, Pushpa K, Tokgözoglu L, Zambon A, Berrou JP, Hermans MP.   +10 more
europepmc   +1 more source

Fenofibrate attenuates hyperhomocysteinemia-potentiated thrombosis by restoring platelet fatty acid β-oxidation. [PDF]

Redox Biol
Han L, Du X, Yan Y, Zhang L, Feng J, Wang X, Zhang X.   +6 more
europepmc   +1 more source

Fenofibrate mitigates microglial activation by reprogramming lipid metabolism and inhibiting ferroptosis. [PDF]

Mol Cell Biochem
Taskesen A, Hacioglu C, Tuncer S, Kilic G, Tuncer C.   +4 more
europepmc   +1 more source

Novel fenofibrate derivatives as cannabinoid receptor ligands

Fenofibrate is a PPARα agonist, used to treat dyslipidemia. Unpublished work that has been previously carried out in our group has identified that fenofibrate also displays affinity for the cannabinoid receptors, CB1 and CB2.
Spencer, Sarah Jane
core  

A 35-Year-Old Woman With Recurrent Hypertriglyceridemia-Induced Pancreatitis in Pregnancy Managed With Fenofibrate and Plasmapheresis. [PDF]

Am J Case Rep
Wang J, Lu Z, Zhou C.
europepmc   +1 more source

Structure-guided optimisation of fenofibrate-derived oxidative phosphorylation inhibitors to modify tumour hypoxia. [PDF]

RSC Med Chem
Holt-Martyn JP, Machado N, Coates JTT, Puliyadi R, Ashton T, Traynor E, Aslam S, Wise TK, Rodriguez-Berriguete G, Schofield CJ, Higgins GS.   +10 more
europepmc   +1 more source

Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats. [PDF]

Res Pharm Sci
Khoshbakht E, Dinarvand N, Yaghooti H, Taheri B, Mohammadtaghvaei N.   +4 more
europepmc   +1 more source